The study met its primary endpoint in enhancing event-free survival over 12 months when compared to historical control groups ...

OS Therapies (OSTX) up 65% in premarket trading after positive phase 2b data on OST-HER2 for lung metastatic osteosarcoma ...

The therapy, dubbed OST-HER2, uses a HER2-bioengineered form of the bacteria Listeria monocytogenes to trigger an immune ...

In recent trading, OS Therapies Inc (OSTX) stock price has shown some volatility, fluctuating -11.02% over the last five trades and -2.24% over the past 30 trades. This represents a notable shift from ...

OS Therapies shares surged Wednesday after the biotech company reported positive data from a clinical trial for its cancer treatment OST-HER2. Shares of the N.Y., clinical-stage biotechnology company ...

OS Therapies shares Phase 2b trial results showing OST-HER2 improves survival rates in rare metastatic osteosarcoma, surpassing historical controls.

With positive data in hand from its phase IIb trial testing immunotherapy candidate OST-HER2 in osteosarcoma, OS Therapies ...

Investing.com -- Shares of OS Therapies, Inc. (NYSE-A: OSTX) surged 58% following the announcement of positive results from its Phase 2b clinical trial for OST-HER2, an immunotherapy candidate ...

HER2 shows promise in Phase 2b osteosarcoma trial, with improved event-free survival at 12 months; company plans to pursue ...

During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and ...

NEW YORK, January 15, 2025--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced ...

Arcellx's anito-cel shows promising efficacy and safety in multiple myeloma. Read why I maintain my hold rating for ACLX ...